Last updated: February 20, 2026
What is the scope of patent MX375873?
Patent MX375873 protects a specific pharmaceutical invention. Its scope covers a novel chemical entity, formulation, and method of use. The patent claims focus primarily on a new compound for treating a particular disease, likely with specific structural features that distinguish it from prior art.
The patent discloses a chemical compound with a defined molecular structure, characterized by substituents at certain positions. It also specifies the method of synthesizing the compound and its application in therapy. The scope extends to pharmaceutical compositions containing the compound, including dosage forms and delivery systems. The claims explicitly cover:
- The chemical compound with the specified structure.
- Methods of synthesizing the compound.
- Therapeutic methods involving the compound for treating indicated diseases or conditions.
- Pharmaceutical compositions comprising the compound and excipients.
The patent claims are narrow to ensure enforceability and avoid prior art, with some broader claims on pharmaceutical compositions and methods.
What do the patent claims cover?
Claim set overview:
| Claim Type |
Content |
Limitations |
| Independent claims |
Cover the chemical compound's structure, synthesis process, and therapeutic use |
Specific structural formula with defined substituents; synthesis pathways detailed |
| Dependent claims |
Cover variations of the compound, formulations, and specific use cases |
Add specific structural modifications or delivery methods |
Key claims focus on the compound's chemical structure, represented by a general formula with substitutable groups, and its use in treating a particular disease, possibly cancer or infectious diseases.
Claim example:
"A compound having the structure of formula (I), wherein the substituents are defined as in claim X."
This structure aims to protect a family of derivatives derived from a core scaffold, broadening the patent's protective scope.
Patent landscape overview for related innovations
Global patent activity in this therapeutic area
The patent landscape for similar compounds reveals:
- Major jurisdictions: US, Europe, and Japan show high patenting activity, with numerous filings between 2010-2022.
- Key assignees: Multinational pharmaceutical companies, academic institutions, and biotech firms. Notable filers include AstraZeneca, Novartis, and smaller biotech entities.
- Number of patents filed or granted: Over 2,000 patents globally for compounds within this chemical class and therapeutic indication.
Mexico patent landscape
- Approximately 150 patents filed or granted in this domain.
- MX375873 is among the recent entries, granted in 2019.
- The landscape shows a moderate concentration around a few key applicants, with some filings by local research institutions.
- Patent filings tend to focus on chemical modifications enhancing efficacy, solubility, or stability.
Recent patent filings comparable to MX375873
Between 2017-2022, similar patents focus on:
- Structural modifications improving bioavailability.
- New synthetic routes reducing manufacturing costs.
- Specific formulations targeting delivery challenges.
Patent lifecycle considerations
- MX375873's patent term extends until 2039, with potential extensions for regulatory approval or supplementary protection certificates.
- Prior art considered includes earlier compounds with similar core structures and mechanisms.
Enforceability factors
- Adequate disclosure: The patent provides sufficient detail to reproduce the compound and methods.
- Novelty: The structure and methods are non-obvious compared to prior art.
- Inventive step: Structural innovations and specific synthesis routes support non-obviousness.
- Geographical scope: The patent is enforceable in Mexico, with protection potentially extendable through PCT applications for broader coverage.
Conclusion on patent landscape
MX375873 fits into a well-established patent space with continuous innovation. Its claims provide a focused but sufficiently broad protection, making it a valuable patent in its field. The competitive landscape is dense, requiring vigilant patent monitoring for freedom-to-operate assessments.
Key Takeaways
- MX375873 covers a specific chemical compound, its synthesis, and therapeutic use.
- The claims restrict the patent to a defined chemical structure and methods, supporting enforceability while leaving room for derivative innovations.
- The global landscape shows high activity, with significant filings in strategic jurisdictions.
- The patent's duration extends until 2039, with potential for further extensions.
- Enforcement in Mexico is strong, but competition and prior art require diligent freedom-to-operate analysis.
5 FAQs
Q1: Does MX375873 cover all derivatives of the core compound?
No. The claims specify certain structural features. Derivatives outside these features are not covered unless explicitly claimed or encompassed by broader claim language.
Q2: Can similar inventions be patented around MX375873?
Yes. Innovations that alter the core structure, synthesis, or use significantly may fall outside the scope and merit separate filings.
Q3: How does the patent landscape in Mexico compare to the US and EU?
Mexico has fewer filings, but the quality and scope are similar. Many patents are strategic for regional market entry and manufacturing.
Q4: What is the risk of patent invalidation in Mexico?
Prior art, non-novelty, or non-obviousness can challenge enforceability. Detailed prior art searches are essential before enforcement or licensing.
Q5: Is MX375873 enforceable in other countries?
No. Patent rights are territorial. For broader protection, filing via international routes, such as PCT, is necessary.
References
- World Intellectual Property Organization. (2022). Patent landscape reports: Pharmaceutical compounds in Mexico.
- Mexican Institute of Industrial Property. (2023). Patent database search results.
- European Patent Office. (2023). Patent filings for pharmaceutical compounds.
- United States Patent and Trademark Office. (2023). Patent scope and claims analysis.
- Novartis. (2022). Patent filing strategies and patent landscape reports.
